S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                  1890--A
 
                        2023-2024 Regular Sessions
 
                             I N  S E N A T E
 
                             January 17, 2023
                                ___________
 
 Introduced  by  Sens. SANDERS, ASHBY, CLEARE, COMRIE, GIANARIS, JACKSON,
   KENNEDY, KRUEGER, MAY, MAYER, MYRIE, PARKER, RAMOS, ROLISON,  SEPULVE-
   DA,  SKOUFIS, WEBB -- read twice and ordered printed, and when printed
   to be committed to the Committee  on  Health  --  recommitted  to  the
   Committee  on  Health  in  accordance  with  Senate  Rule 6, sec. 8 --
   reported favorably from said committee and committed to the  Committee
   on Finance -- committee discharged, bill amended, ordered reprinted as
   amended and recommitted to said committee
 
 AN  ACT  to amend the public health law, in relation to establishing the
   "Syd O. Sotillo Sickle Cell Treatment Act"
 
   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section  1.  Short  title. This act shall be known and may be cited as
 the "Syd O. Sotillo Sickle Cell Treatment Act".
   § 2. The public health law is amended by adding a new section  2807-bb
 to read as follows:
   § 2807-BB. SICKLE CELL CENTERS FOR EXCELLENCE AND OUTPATIENT TREATMENT
 CENTERS.  1.  CENTERS  FOR SICKLE CELL CARE EXCELLENCE. THE COMMISSIONER
 SHALL DESIGNATE FIVE GENERAL HOSPITALS OR HOSPICES UNDER  ARTICLE  FORTY
 OF THIS CHAPTER, UPON SUCCESSFUL APPLICATION, AS CENTERS FOR SICKLE CELL
 CARE  EXCELLENCE.  THE DESIGNATIONS SHALL BE MADE THROUGH AN APPLICATION
 DESIGNED BY THE DEPARTMENT, AND BASED ON  SERVICE,  STAFFING  AND  OTHER
 CRITERIA  AS  DEVELOPED  BY  THE COMMISSIONER. THE CENTERS OF EXCELLENCE
 SHALL PROVIDE SPECIALIZED SICKLE CELL DISEASE CARE,  TREATMENT,  PALLIA-
 TIVE  CARE, EDUCATION AND RELATED SERVICES AND SHALL CONDUCT SPECIALIZED
 RESEARCH INTO THE CARE, TREATMENT AND MANAGEMENT OF SICKLE CELL DISEASE.
 DESIGNATION AS A CENTER FOR SICKLE CELL CARE EXCELLENCE SHALL NOT  ENTI-
 TLE  A CENTER TO ENHANCED REIMBURSEMENT, BUT MAY BE UTILIZED IN OUTREACH
 AND OTHER PROMOTIONAL ACTIVITIES.  EACH  CENTER  FOR  SICKLE  CELL  CARE
 EXCELLENCE  SHALL  AFFILIATE  AND COOPERATE WITH MAJOR CENTERS OF HIGHER
 LEARNING, INCLUDING MEDICAL COLLEGES, AND LIFE SCIENCE  RESEARCH  INSTI-
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD05963-02-4
              

 S. 1890--A                          2
 
 TUTES  IN  THE STATE.  THE STATE UNIVERSITY SHALL ENTER INTO APPROPRIATE
 LEGAL AGREEMENTS TO ENABLE THIS COOPERATION. EACH CENTER FOR SICKLE CELL
 CARE EXCELLENCE SHALL RECEIVE TWO HUNDRED THOUSAND DOLLARS PER YEAR FROM
 THE  DEPARTMENT,  FROM AMOUNTS APPROPRIATED FOR THAT PURPOSE, TO BE USED
 ON SICKLE CELL DISEASE RESEARCH.
   2. OUTPATIENT TREATMENT CENTERS. THE COMMISSIONER SHALL DESIGNATE  TEN
 HOSPITALS,  DISTRIBUTED  BASED ON SICKLE CELL PATIENT POPULATION CONCEN-
 TRATIONS, AS  SICKLE  CELL  OUTPATIENT  TREATMENT  CENTERS  WHICH  SHALL
 PROVIDE  PATIENTS  TREATMENT  FOR  SICKLE CELL DISEASE AS AN OUTPATIENT.
 EACH SICKLE CELL OUTPATIENT TREATMENT CENTER SHALL RECEIVE  ONE  HUNDRED
 THOUSAND DOLLARS PER YEAR FROM THE DEPARTMENT, FROM AMOUNTS APPROPRIATED
 FOR  THAT PURPOSE, TO BE USED TO ENSURE THE PROPER MANAGEMENT AND EQUIP-
 PING OF THE CENTERS TO CARE FOR SICKLE CELL PATIENTS.
   § 3. Subdivision 8 of section 3331 of the public health law, as  added
 by  section  7-a of part D of chapter 57 of the laws of 2018, is amended
 to read as follows:
   8. No opioids shall be prescribed to a  patient  initiating  or  being
 maintained on opioid treatment for pain which has lasted more than three
 months  or  past  the  time of normal tissue healing, unless the medical
 record contains a written treatment plan that follows generally accepted
 national professional or governmental guidelines.  The  requirements  of
 this  paragraph  shall  not  apply in the case of patients who are being
 treated for cancer OR SICKLE CELL DISEASE that is not in remission,  who
 are in hospice or other end-of-life care, or whose pain is being treated
 as part of palliative care practices.
   § 4. This act shall take effect immediately.